New breast cancer drug cocktail shows 'unprecedented' boost to patient's lifespan

September 29, 2014 5:11 PM

15 0

A new breast cancer drug from Roche has shown 'unprecedented' benefits in extending lives in a clinical trial.

Patients with a type of breast cancer known as HER2 positive, which makes up about a quarter of all breast cancers, who were given Perjeta on top of older medicine Herceptin and chemotherapy lived 15.7 months longer than those on Herceptin and chemotherapy alone.

Read more

To category page